Oncoheroes Biosciences Secures Additional Venture Philanthropy Investment
An additional venture philanthropy organization, the Catalytic Impact Foundation, which supports women’s health, brain health, children’s health, aging, and pediatric rare disease initiatives, is investing in AIM-HI Accelerator Fund portfolio company Oncoheroes Biosciences, further validating the start-up’s unique effort to…
SciTech Development Presenting at the 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference
The AIM-HI Accelerator Fund is proud to support our Portfolio Company, SciTech Development, to present at the Virtual 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event will take place on January 11-12, 2021, co-hosted…
AIM-HI Women’s Venture Competition Sponsor: Microsoft
The AIM-HI Accelerator Fund sincerely thanks Microsoft for being a generous sponsor and supporting our inaugural Women’s Venture Competition program to provide various opportunities to women-led oncology start-ups! Only 2% of all venture money go to women-led early stage companies.…
Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum
Tvardi Therapeutics, an AIM-HI Accelerator Fund portfolio company, has won recognition as one of the ten “Most Promising” companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is…
Oncoheroes Biosciences’ Pediatric Cancer Drug Candidate Receives Orphan Drug Designation
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare…
Congratulations to our Top Two Finalists and the People’s Choice Award Winner!
Congratulations to the inaugural AIM-HI Women’s Venture Competition finalists selected by the Judging Committee, Stacy Blain of Concarlo Holdings and Manijeh Goldberg of Privo Technologies. Not only are they advancing science, but they are also paving the way for more…
Support Women Scientist-Entrepreneurs in Celebration of the Women’s Equality Day
It’s 2020, and still only 2.2% of all venture capital dollars go to companies led by women entrepreneurs in life sciences. Let’s change that! Join us on Thursday, September 24, at the AIM-HI Women’s Venture Competition Award Ceremony as we celebrate…
AIM-HI Portfolio Company Profile: Rasio Therapeutics
Serial entrepreneur Ken Malone, Ph.D., and his team of scientists and business executives are at the forefront of developing cutting-edge biohealth companies. Malone is the Chairman of the Board of Directors of Rasio Therapeutics, a start-up which is bringing innovative…
AIM-HI Announces Semi-Finalists in Women’s Venture Competition, Finalists Announced Sept. 24
The 8 semi-finalists are just announced in the AIM-HI Accelerator Fund's inaugural Women’s Venture Competition! These innovative oncology startups are selected from an exceptional pool of high quality women entrepreneur applications, by a Selection Committee comprised of world-class key opinion…
AIM-HI Portfolio Company Profile: Tvardi Therapeutics
Imran Alibhai, Ph.D., is the CEO of Tvardi Therapeutics, a biopharmaceutical company developing breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. The National Foundation for Cancer Research and AIM-HI Accelerator Fund have been early financial supporters of…
Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research
Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its…
AIM-HI Portfolio Company Profile: InterLeukin Combinatorial Therapies
Paul B. Fisher, M.Ph., Ph.D., co-founded InterLeukin Combinatorial Therapies with hopes of developing a product that destabilizes and kills cancer cells. The Director of Virginia Commonwealth University’s Institute of Molecular Medicine, Fisher represents a world-class scientist with knowledge also of…